{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:13:25Z","timestamp":1780636405770,"version":"3.54.1"},"reference-count":97,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The present-day management of hepatitis B virus (HBV) infection relies on constant and appropriate monitoring of viral activity, disease progression and treatment response. Traditional HBV infection biomarkers have many limitations in predicting clinical outcomes or therapy success. Quantitation of HBV core antibodies (qAnti-HBc) is a new non-invasive biomarker that can be used in solving multiple diagnostic problems. It was shown to correlate well with infection phases, level of hepatic inflammation and fibrosis, exacerbations during chronic infection and presence of occult infection. Further, the level of qAnti-HBc was recognised as predictive of spontaneous or therapy-induced HBeAg and HBsAg seroclearance, relapse after therapy discontinuation, re-infection after liver transplantation and viral reactivation upon immunosuppression. However, qAnti-HBc cannot be relied upon as a single diagnostic test to solve all dilemmas, and its diagnostic and prognostic power can be much improved when combined with other diagnostic biomarkers (HBV DNA, HBeAg, qHBsAg and anti-HBs antibodies). The availability of commercial qAnti-HBc diagnostic kits still needs to be improved. The comparison of results from different studies and definitions of universal cut-off values continue to be hindered because many methods are only semi-quantitative. The clinical utility of qAnti-HBc and the methods used for its measurement are the focus of this review.<\/jats:p>","DOI":"10.3390\/v15020373","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T07:34:41Z","timestamp":1675064081000},"page":"373","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-1378","authenticated-orcid":false,"given":"Ivana","family":"Lazarevic","sequence":"first","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-096X","authenticated-orcid":false,"given":"Ana","family":"Banko","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9446-8701","authenticated-orcid":false,"given":"Danijela","family":"Miljanovic","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Cupic","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J. Viral Hepat."},{"key":"ref_2","unstructured":"World Health Organization (2022). Hepatitis B, World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_3","unstructured":"World Health Organization (2017). WHO Guidelines on Hepatitis B and C Testing, World Health Organization. Available online: https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1080581\/retrieve."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104553","DOI":"10.1016\/j.antiviral.2019.104553","article-title":"Non-invasive biomarkers for chronic hepatitis B virus infection management","volume":"169","author":"Charre","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2018.11.037","article-title":"New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection","volume":"156","author":"Coffin","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Vachon, A., and Osiowy, C. (2021). Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management. Viruses, 13.","DOI":"10.3390\/v13060951"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-0039-3401031","article-title":"Role of Biomarkers in Guiding Cure of Viral Hepatitis B","volume":"40","author":"Buti","year":"2020","journal-title":"Semin. Liver Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3350\/cmh.2020.0032","article-title":"Novel biomarkers for the management of chronic hepatitis B","volume":"26","author":"Inoue","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1126\/science.3491425","article-title":"The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen","volume":"234","author":"Milich","year":"1986","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nri1573","article-title":"Immunology of hepatitis B virus and hepatitis C virus infection","volume":"5","author":"Rehermann","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_12","first-page":"203","article-title":"Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations","volume":"8","author":"Bellati","year":"1993","journal-title":"Arch. Virol. Suppl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Taormina Workshop on Occult HBV Infection Faculty Members Update of the statements on biology and clinical impact of occult hepatitis B virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Holtkamp, C., Fiedler, M., Dittmer, U., and Anastasiou, O.E. (2022). The Course of Anti-HBc Antibodies over Time in Immunocompromised Hosts. Vaccines, 10.","DOI":"10.3390\/vaccines10020137"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1128\/CVI.00457-09","article-title":"Novel double-antigen sandwich immunoassay for human hepatitis B core antibody","volume":"17","author":"Li","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_16","unstructured":"(2013). Medicines & Healthcare products Regulatory Agency WHO International Standard: First International Standard for Anti-Hepatitis B Core Antigen (Standard No. NIBSC 95\/5223). Available online: https:\/\/www.nibsc.org\/documents\/ifu\/95-522.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1515\/cclm-2012-0098","article-title":"Performance evaluation of three different immunoassays for detection of antibodies to hepatitis B core","volume":"51","author":"Bin","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_18","first-page":"119","article-title":"Characteristics of hepatitis B core antibody level in the natural history of chronic hepatitis B","volume":"26","author":"Wang","year":"2018","journal-title":"Discov. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4133283","DOI":"10.1155\/2022\/4133283","article-title":"Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Na\u00efve Chronic HBV-Infected Patients","volume":"2022","author":"Liao","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"114985","DOI":"10.1016\/j.diagmicrobio.2020.114985","article-title":"Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection","volume":"96","author":"Caviglia","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cerva, C., Salpini, R., Alkhatib, M., Malagnino, V., Piermatteo, L., Battisti, A., Bertoli, A., Gersch, J., Holzmayer, V., and Kuhns, M. (2022). Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020443"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7754\/Clin.Lab.2014.140504","article-title":"Performance evaluation of four dominant anti-hepatitis B core antigen (HBcAb) kits in Japan for preventing de novo hepatitis B virus (HBV) infection","volume":"61","author":"Kobayashi","year":"2015","journal-title":"Clin. Lab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/infdis\/jiaa538","article-title":"Erratum to: Kinetics of Hepatitis B Core-Related Antigen and Anti-Hepatitis B Core Antibody and Their Association with Serological Response in Human Immunodeficiency Virus-Hepatitis B Coinfection","volume":"223","author":"Dezanet","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/jvh.13315","article-title":"Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and\/or precore mutations","volume":"27","author":"Li","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"14093","DOI":"10.1038\/s41598-017-14427-4","article-title":"Europium (III) chelate microparticle-based lateral flow immunoassay strips for rapid and quantitative detection of antibody to hepatitis B core antigen","volume":"7","author":"Liang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"114226","DOI":"10.1016\/j.jviromet.2021.114226","article-title":"Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection","volume":"296","author":"Zhang","year":"2021","journal-title":"J. Virol. Methods"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cmi.2014.10.002","article-title":"Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection","volume":"21","author":"Song","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1097\/MD.0000000000000322","article-title":"Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B: A prospective observational study","volume":"93","author":"Jia","year":"2014","journal-title":"Medicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3720571","DOI":"10.1155\/2021\/3720571","article-title":"Clinical Diagnostic Value of Quantitative Hepatitis B Virus Core Antibody Test in Chronic Viral Hepatitis B","volume":"2021","author":"Su","year":"2021","journal-title":"Bioinorg. Chem. Appl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101563","DOI":"10.1016\/j.clinre.2020.10.008","article-title":"Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy","volume":"45","author":"Chi","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.cgh.2018.09.037","article-title":"Association Between High Levels of Hepatitis B Core Antibody and Seroclearance of Hepatitis B e Antigen in Individuals with Chronic Hepatitis B Virus Infection","volume":"17","author":"Liu","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/hep.30788","article-title":"Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Children With a Normal Alanine Aminotransferase Level","volume":"70","author":"Chen","year":"2019","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cgh.2018.04.064","article-title":"Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients","volume":"17","author":"Hu","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/liv.13416","article-title":"Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance","volume":"37","author":"Oliveri","year":"2017","journal-title":"Liver Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3350\/cmh.2019.0060","article-title":"The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: Is quantitative serology the answer?","volume":"26","author":"Lall","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/jgh.15310","article-title":"Prognostic value of anti-HBc quantification in hepatitis B virus related acute-on-chronic liver failure","volume":"36","author":"Li","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jhep.2018.03.021","article-title":"Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection","volume":"69","author":"Caviglia","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/gutjnl-2018-317385","article-title":"Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus","volume":"68","author":"Yang","year":"2019","journal-title":"Gut"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2018.02.033","article-title":"Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection","volume":"69","author":"Yang","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Salpini, R., Malagnino, V., Piermatteo, L., Mulas, T., Alkhatib, M., Scutari, R., Teti, E., Cerva, C., Yu La Rosa, K., and Brugneti, M. (2020). Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive\/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. Microorganisms, 8.","DOI":"10.3390\/microorganisms8111819"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jmv.27327","article-title":"Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA","volume":"94","author":"Yao","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1038\/s41598-017-03102-3","article-title":"Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"105315","DOI":"10.1016\/j.antiviral.2022.105315","article-title":"A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT \u2264 ULN","volume":"202","author":"Feng","year":"2022","journal-title":"Antiviral Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.3748\/wjg.v27.i21.2910","article-title":"Prediction of hepatic inflammation in chronic hepatitis B patients with a random forest-backward feature elimination algorithm","volume":"27","author":"Zhou","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6545642","DOI":"10.1155\/2019\/6545642","article-title":"(Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection","volume":"2019","author":"Zhang","year":"2019","journal-title":"Can. J. Infect Dis. Med Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1002\/jmv.27779","article-title":"Dose-response relationship between qAnti-HBc and liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase based on liver biopsy","volume":"94","author":"Zhang","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e4422","DOI":"10.1097\/MD.0000000000004422","article-title":"Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-na\u00efve chronic hepatitis B patients","volume":"95","author":"Li","year":"2016","journal-title":"Medicine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"E133","DOI":"10.1111\/hepr.12937","article-title":"Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels","volume":"48","author":"Li","year":"2018","journal-title":"Hepatol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/jgh.15881","article-title":"Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients","volume":"37","author":"Wang","year":"2022","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11063","DOI":"10.18632\/oncotarget.14323","article-title":"Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-na\u00efve patients with chronic hepatitis B","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jcma.2018.05.007","article-title":"Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-na\u00efve CHB patients","volume":"81","author":"Li","year":"2018","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.dld.2017.12.028","article-title":"A novel noninvasive index for the prediction of moderate to severe fibrosis in chronic hepatitis B patients","volume":"50","author":"Li","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"ofaa215","DOI":"10.1093\/ofid\/ofaa215","article-title":"Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody with Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir","volume":"7","author":"Cruchet","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_54","first-page":"13524","article-title":"Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization","volume":"8","author":"Yuan","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"710528","DOI":"10.3389\/fimmu.2021.710528","article-title":"Baseline Quantitative Hepatitis B Core Antibody Titer Is a Predictor for Hepatitis B Virus Infection Recurrence after Orthotopic Liver Transplantation","volume":"12","author":"Lou","year":"2021","journal-title":"Front Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gutjnl-2014-308546","article-title":"Chronic Hepatitis B Study Consortium Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues","volume":"65","author":"Fan","year":"2016","journal-title":"Gut"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/gutjnl-2012-302656","article-title":"Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients","volume":"62","author":"Yuan","year":"2013","journal-title":"Gut"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"218","DOI":"10.7150\/thno.10636","article-title":"Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon","volume":"5","author":"Hou","year":"2015","journal-title":"Theranostics"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/jvh.12626","article-title":"Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir","volume":"24","author":"Xu","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/IDR.S163038","article-title":"Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs","volume":"11","author":"Cai","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/13596535211059895","article-title":"A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients","volume":"26","author":"Fang","year":"2021","journal-title":"Antivir. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/infdis\/jiac210","article-title":"Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients","volume":"227","author":"Brakenhoff","year":"2022","journal-title":"J. Infect Dis."},{"key":"ref_63","first-page":"837","article-title":"Correlation of qAnti-HBc with antiviral efficacy in children with chronic hepatitis B and exploration of its possible immune mechanism","volume":"29","author":"Zhou","year":"2021","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Yuan, Q., Song, L.W., Cavallone, D., Moriconi, F., Cherubini, B., Colombatto, P., Oliveri, F., Coco, B.A., Ricco, G., and Bonino, F. (2015). Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130209"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"894410","DOI":"10.3389\/fimmu.2022.894410","article-title":"Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-\u03b1 in NA-suppressed chronic hepatitis B patients","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10620-021-06845-2","article-title":"Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance","volume":"67","author":"Kim","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_67","first-page":"673","article-title":"Quantitative hepatitis B core antibody levels can be used as a predictive index of HBsAg clearance","volume":"29","author":"Lin","year":"2021","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jfma.2017.11.012","article-title":"Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B","volume":"117","author":"Tseng","year":"2018","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2018.05.047","article-title":"Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated with Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy","volume":"17","author":"Chi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jmii.2019.09.004","article-title":"Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance","volume":"54","author":"Wu","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"879835","DOI":"10.3389\/fimmu.2022.879835","article-title":"Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients with Recurrence of Hepatitis B After Functional Cure","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jhep.2020.01.024","article-title":"Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV","volume":"73","author":"Vanwolleghem","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/jgh.13338","article-title":"Different precore\/core mutations of hepatitis B interact with, limit, or favor liver fibrosisseverity","volume":"31","author":"Ducancelle","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/infdis\/jiac168","article-title":"Clearance of Hepatitis B e Antigen in Untreated Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-analysis","volume":"226","author":"Mohareb","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27083","article-title":"Distinct seromarkers predict different milestones of chronic hepatitis B progression","volume":"60","author":"Liu","year":"2014","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.28552","article-title":"Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers with Low Risk of Disease Progression","volume":"64","author":"Liu","year":"2016","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/jmv.1890130411","article-title":"Diagnostic value of anti-HBc IgM in high HBV prevalence areas","volume":"13","author":"Papaevangelou","year":"1984","journal-title":"J. Med. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/hep.24732","article-title":"Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels","volume":"55","author":"Dao","year":"2012","journal-title":"Hepatology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.3748\/wjg.v21.i13.3953","article-title":"Differentiation of acute and chronic hepatitis B in IgM anti-HBc positive patients","volume":"21","author":"Park","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/17474124.2018.1426459","article-title":"Acute-on-chronic liver failure in chronic hepatitis B: An update","volume":"12","author":"Zhao","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Saitta, C., Pollicino, T., and Raimondo, G. (2022). Occult Hepatitis B Virus Infection: An Update. Viruses, 14.","DOI":"10.3390\/v14071504"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Moretto, F., Catherine, F.X., Esteve, C., Blot, M., and Piroth, L. (2020). Isolated Anti-HBc: Significance and Management. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010202"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","article-title":"Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy","volume":"90","author":"Yeo","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","article-title":"Immunosuppression and HBV reactivation","volume":"33","author":"Shouval","year":"2013","journal-title":"Semin. Liver Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: A prospective study","volume":"32","author":"Seto","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2007.07.022","article-title":"The clinical significance of persistently normal ALT in chronic hepatitis B infection","volume":"47","author":"Lai","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/hep.21585","article-title":"Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels","volume":"45","author":"Lin","year":"2007","journal-title":"Hepatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/atm.2017.01.28","article-title":"Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection","volume":"5","author":"Parikh","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/jmv.24067","article-title":"Direct role of antibody-secreting B cells in the severity of chronic hepatitis B","volume":"87","author":"Zgair","year":"2015","journal-title":"J. Med. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4254\/wjh.v10.i3.352","article-title":"Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management","volume":"10","author":"Chauhan","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e00046-19","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.510300313","article-title":"Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group","volume":"30","author":"Chien","year":"1999","journal-title":"Hepatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bpg.2017.05.003","article-title":"Hepatitis B virus infection and the immune response: The big questions","volume":"31","author":"Boeijen","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/373\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:17:43Z","timestamp":1760120263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":97,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["v15020373"],"URL":"https:\/\/doi.org\/10.3390\/v15020373","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]}}}